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Abstract
Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with
neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.
Methods: We compared two groups of patients with a fairly similar prognosis either receiving Aflibercept or
Ranibizumab within a pro re nata regimen for 1 year. Changes in visual acuity (letters) and central foveal thickness
(CFT) and frequency of injections after completing the loading phase were evaluated using two separate
multivariate mixed linear models.
Results: When correcting for baseline differences between the Aflibercept (11 eyes) and Ranibizumab (16 eyes)
group, there was neither divergence in visual acuity (−0.97 letters (95 % CI. −6.06-4.12); p = 0.709), nor a significant
difference in the reduction of CFT (−25.16 μm, 95 % CI; (−78.01-27.68); p = 0.351) between the two groups 1 year
after treatment initiation. Also, the number of injection did not differ (0.04 (95 % CI; −0.16-0.09); p = 0.565).
Conclusion: In contrast to health claims, treatment-naïve nvAMD, Ranibizumab and Aflibercept were equivalent in
terms of functional and morphologic outcomes and number of injections when studied in real-life clinical practice.
Background
Due to its higher binding affinity and longer duration of
action, Aflibercept (Eylea®, Regeneron, Tarrytown, New
York, USA and Bayer HealthCare, Berlin, Germany) has
theoretical advantages over Ranibizumab (Lucentis®,
Gentech Inc., South San Francisco, CA, USA and Novartis
AG, Basel Switzerland) [1, 2] in neovascular age-related
macular degeneration (nvAMD) management, but empir-
ical evidence quantifying the extent to which this trans-
lates into clinical practice is sparse. The recombinant
fusion protein Aflibercept was licensed in October 2012
for treatment of nvAMD in Switzerland after the VIEW
study [3, 4] showed its comparability in efficacy and safety
to Ranibizumab. In contrast to Ranibizumab that only
binds to VEGF-A [2, 5, 6], Aflibercept also binds to
VEGF-B and the Placental Growth Factor, two additional
factors of neovascularization [7, 8]. A mathematical model
revealing a stronger binding affinity of Aflibercept to
VEGF165 than Ranibizumab suggested that treatment
intervals can be extended due to the longer duration of
action [9].
However, even though clinical evidence that would
allow for only bimonthly treatment with Aflibercept ex-
ists [3, 10], physicians often apply just the same ‘pro re
nata’ (PRN) regimen with monthly check-ups and treat-
ment if needed that was established for Ranibizumab in
the PrONTO-studies [11, 12]. When applying the PRN
regimen to Aflibercept during the second year of the
VIEW-Trial [4], it was found that the new drug
required fewer injections than Ranibizumab. But, a
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recent US American study, assessing the current use of
Ranibizumab and Aflibercept in a real-life setting,
found no differences regarding the therapeutic use of
the two drugs [13]. Another recent health service re-
search study corroborated these findings [14]. Unfortu-
nately, both studies did not assess clinical outcomes
associated with treatment. Therefore, in this 1-year
retrospective analysis, we compared two groups of pa-
tients with treatment-naïve nvAMD and fairly similar
prognosis either receiving Aflibercept or Ranibizumab
at practitioner’s discretion and compared therapeutic
use and corresponding clinical outcomes.
Methods
A retrospective, comparative study of consecutive pa-
tients treated at the Eye Clinic of the Cantonal Hospital
Lucerne (LUKS) over a 1 year period was conducted
after seeking the approval of the ethics committee of
Canton Lucerne. We retrospectively identified in our
electronic medical records all patients who were started
on either Ranibizumab or Aflibercept between 01.11.2012
and 31.12.2012 for the indication of newly diagnosed and
therefore treatment-naïve nvAMD in at least one eye. Be-
cause of the retrospective nature of this study, no in-
formed consent was obtained. We included patients with
an observation period of at least 12 months, attending
monthly follow-up visits where testing of best corrected
visual acuity (BCVA) and optical coherence tomography
(OCT) was performed For inclusion, patients needed the
diagnosis of nvAMD secured by fluoresceine angiography
beforehand. We included all patients with newly diag-
nosed and treatment-naive nvAMD. Since no information
about the evolution of preliminary vision loss was avail-
able decisions for inclusion were not affected by this. All
handwritten clinical records were manually searched for
exclusion criteria. Exclusion criteria included: co-existence
of visually significant ocular conditions (diabetic retinop-
athy, n = 1; non arteriitic anterior ischemic opticus neur-
opathy, n = 1), cataract surgery in the study eye within the
year of follow-up (n = 4), YAG-capsulotomy in the study
eye during follow-up (n = 0), conversion from one
substance to another (Ranibizumab to Aflibercept, n = 6;
Aflibercept to Ranibizumab, n = 1), insufficient clinical re-
cords (n = 1) and additional treatment for nvAMD (n = 0).
Three patients were excluded for not receiving the initial
loading dose and one patient was excluded because of
intermediate discontinuation of treatment. When condi-
tions stabilized, defined as absence of indication for intra-
vitreal injection for at least 6 months, patients were
henceforth cared for by their attending physician. This oc-
curred in two patients, who were excluded from the
analysis.
Patients suffering from cataract in the study eye were
not primarily excluded, since this study is investigating
the change in BCVA compared to baseline measure-
ment. However, patients who underwent cataract surgery
or - if already pseudophakic - a YAG-capsulotomy due
to after-cataract during the time of follow-up in the
study eye were excluded in order to prevent any biases
arising from sudden gain in BCVA. The final study
population consisted of 27 eyes of 24 patients, 16 eyes of
15 patients treated with Ranibizumab and 11 eyes of 9
patients treated with Aflibercept.
Whether patients were started on Ranibizumab or
Aflibercept was decided at the practitioner’s discretion at
first visit and under the assumption of similar efficacy as
no proof of superiority for the one or the other substance
in specific features of nvAMD was available. Therefore,
the assignment was considered quasi-random, even more
so as several practitioners were involved. All eyes included
in this study had initially received a series of 3 monthly in-
jections of either Ranibizumab or Aflibercept, afterwards
treatment with both substances was continued in a PRN
regimen. Retreatment criteria based on OCT included any
existence of intraretinal or subretinal fluid, increase in
retinal thickness >20um compared with the previous
scan as well as increase of size of pigment epithelial de-
tachment (PED) compared with the previous scan.
Clinically, a newly detected macular haemorrhage in
biomicroscopy accounted for the indication of retreat-
ment. Futhermore, the visual development was carefully
monitored and may have been taken into consideration
in cases ambiguous by OCT.
Demographic data including patient age (at baseline)
and gender, number of injections, BCVA and central fo-
veal thickness (CFT) in OCT in included patients were
explored (Table 1). We measured BCVA using the Early
Treatment Diabetic Retinopathy Study (ETDRS) scale
with best correction. Retinal images and automatic
follow-up horizontal 13-line raster scans with automatic-
ally measured CFT were obtained with Spectralis-OCT
(Heidelberg Engineering GmbH, 69121 Heidelberg,
Germany) and evaluated with Heidelberg Eye Explorer
(Version 1.7.1.0., ©2012, Heidelberg Engineering GmbH,
69121 Heidelberg, Germany). BCVA assessments as well
as OCT measurements were conducted by experienced
optometrists.
Every OCT included in this study was manually revised
and corrected if the automatic drawing of the inner limit-
ing membrane and Bruch membrane necessary for meas-
urement of the CFT were inaccurate. Furthermore, every
patient’s nvAMD was classified in “predominantly classic”
or “predominantly occult” on the basis of pre-therapeutic
fluorescence angiography by an experienced retinologist.
Outcome was measured by change in BCVA and
change in CFT measured by OCT after a treatment-
period of 12 months with either substance compared to
the values obtained after the loading dose, therefore
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4 months after the initiation of treatment, which is con-
sistent with the beginning of the PRN regimen. Further-
more, the number of injections needed in a PRN
treatment regimen with the same retreatment criteria
[11, 12] used for both substances was compared between
the two groups.
Statistical analyses
Sample size and power: We considered the two treat-
ments to be equal if the difference in the average
number of injections/year would be less than 10 %
(non-inferiority margin). When enrolling 10 patients
per treatment group and further assuming a standard
deviation of this difference to be 0.5, the power would
be 0.922.
We summarised continuous variables with means and
standard deviations. Dichotomous variables are presented
with percentages. Differences in population characteristics
between patients receiving Ranibizumab and Aflibercept
were tested using t-tests. A p-value of less than 5 % was
considered as statistically significant.
Associations between changes in BCVA or CFT mea-
sured by OCT and type of treatment (Ranibizumab or
Aflibercept) after completing the 3 month loading phase,
were assessed with two multivariate mixed linear
models. On one side, these models took into account
that patients had provided repeated measurements dur-
ing follow-up. To account for the fact that some patients
provided data on both eyes, an indicator variate for “pa-
tient” was introduced as a random factor. Second, since
differences in the distribution of parameters at baseline
were present and therefore could introduce confound-
ing, we accounted for these differences entering the two
parameters with the largest differences between groups
(letter values (continuous variate) and CFT values (con-
tinuous variate)) as additional parameters to the models.
Table 1 Comparison of salient patients’ characteristicsa between the Ranibizumab and Aflibercept group at baseline, after
completing the loading dose phase and after 1 year
Ranibizumab (16 eyes) Aflibercept (11 eyes) Difference Confidence interval p-value
Baseline
Age (mean ± SD) [years] 77.6 ± 9.20 75 ± 6.74 2.63 −4.08 to 9.33 0.428
Female gender n (%) 11 (68.8 %) 8 (72.7 %) 0.586
Right eye n (%) 7 (43.8 %) 6 (54.5 %) 0.436
Cataract n (%) 9 (56.3 %) 9 (81.8 %) 0.167
Serous PED n (%) 3 (18.8 %) 2 (18.2 %) 0.684
Classic CNV n (%) 7 (43.8 %) 3 (27.3 %) 0.324
Loading phase
Letters before treatment (mean ± SD) 52.25 ± 23.38 62.55 ± 22.20 −10.30 −28.78 to 8.19 0.262
CFT before treatment (mean ± SD) [μm] 492.80 ± 165.60 352.50 ± 168.51 140.36 5.83 to 274.88 0.042
Letters after loading dose (mean ± SD) 66.06 ± 10.49 68.91 ± 8.51 −2.85 −10.71 to 5.01 0.463
CFT after loading dose (mean ± SD) [μm] 323.75 ± 93.00 267.73 ± 65.18 56.02 −10.93 to 122.98 0.097
1 year
Letters after 1 year (mean ± SD) 67.25 ± 12.69 68.18 ± 13.06 −0.93 −11.29 to 9.43 0.856
CFT after 1 year (mean ± SD) [μm] 337.31 ± 110.14 274.00 ± 77.76 63.31 −16.13 to 142.75 0.113
Number of injections/year 8.28 ± 2.07 8.49 ± 1.97 −0.22 −1.85 to 1.42 0.787
aDescriptives were based on eyes
Table 2 Comparison of development of CFT and BCVA of the Ranibizumab and the Aflibercept group after the loading dose and
after 1 year, respectively
Ranibizumab (16 eyes) Aflibercept (11 eyes) Difference Confidence interval p-value
Loading phase
Change of Letters after loading dose(mean ± SD) 13.81 ± 20.48 6.36 ± 15.46 7.45 −7.58 to 22.48 0.317
Change of CFT after loading dose (mean ± SD) [μm] −169.06 ± 140.60 −84.73 ± 143.65 −84.34 −198.74 to 30.07 0.142
1 year
Change of Letters after 1 year (mean ± SD) 15.00 ± 21.77 5.64 ± 12.64 9.36 −5.69 to 24.41 0.212
Change of CFT after 1 year (mean ± SD) [μm] −155.50 ± 160.14 78.45 ± 165.83 −77.05 −208.08 to 53.99 0.237
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Analyses were performed using the Stata 11.2 statistics
software package. (StataCorp. 2009. Stata Statistical
Software: Release 11. College Station, TX: StataCorp LP.)
Results
Nine patients (11 eyes) with an average age of 75.0 years
(SD 6.74) started with Aflibercept and 15 patients (16
eyes) with an average age of 77.6 years (SD 9.2) started
with Ranibizumab. The proportion of female patients
was similar between the two groups ((8/11) 72.7 %
(Aflibercept) vs. (11/16) 68.8 % (Ranibizumab); 1-sided
Fisher’s exact test p = 0.586). Further population
characteristics are presented in Table 1. There were no
documented SAEs in neither the ranibizumab nor the
aflibercept group.
Patients receiving Aflibercept had a better average
starting visual acuity compared to patients receiving
Ranibizumab (difference 10.30 letters, standard devi-
ation (SD): 8.98; p = 0.262). Moreover, the baseline CFT
of patients receiving Aflibercept was significantly lower
compared to patients on Ranibizumab (mean difference
140.4 μm (95 % CI; 5.83 to 274.88); p = 0.042).
When correcting for differences in BCVA at baseline be-
tween groups there was no difference within 1 year of
follow-up ((−0.97 letters (95 % CI. −6.06 to 4.12); p = 0.709)
with a mean letter value of 67.25 (SD 12.69) for ranibi-
zumab and 68.18 (SD 13.06) for aflibercept. When cor-
recting for these baseline differences, there was also no
significant difference in the reduction of CFT between
the two groups within 1 year (−25.16 μm, 95 % CI;
(−78.01 to 27.68); p = 0.351). The number of injections
was also similar (mean difference 0.04 (95 % CI; −0.16
to 0.09); p = 0.565), with an absolute number of 8.28 in-
jections per 365 days (SD 2.07, CI 95 % 7.18 to 9.38)
for ranibizumab and 8.49 injections/365 days (SD 1.97,
CI 95 % 7.17 to 9.82) for patients under aflibercept
treatment.
Effect of loading dose on BCVA and CFT
For Ranibizumab, BCVA (mean difference 13.81 letters,
(SD 6.41); p = 0.039) and CFT (mean difference
169.1 μm (SD 47.5); p = 0.001) improved significantly. In
patients receiving Aflibercept these improvements were
smaller and not significant (BCVA mean difference 6.36
letters, (SD 7.17); p = 0.386) and CFT (mean difference
84.7 μm (SD 54.5); p = 0.136).
Effects during follow-up
After completing the loading phase, injections were asso-
ciated with a small albeit non-significant improvement of
letters 0.02 (95 % CI: −0.17 to 0.22) p = 0.802) There was
also a non-significant increase of CFT after 1 year in all
patients (+56.09 (95 % CI: −197.95 to 310.13) p = 0.647)
which was also similar between the two patient groups.
Changes of letters and CFT after completing the loading
phase and 1 year are shown in Table 2.
Discussion
Main findings
In this retrospective real-life clinical assessment of previ-
ously untreated patients with nvAMD, Aflibercept being
featured with longer duration of action and stronger
binding affinity showed no advantages over Ranibizumab
when treating for one-year. As first-line treatments of
nvAMD, both substances were equivalent in terms of in-
jection frequency and visual outcome. Moreover, no sta-
tistically significant differences were found between CFT
changes along 1 year of follow-up between both treat-
ment groups.
Implications for research
Basic scientific enquiry showed that Aflibercept has a
binding affinity to various types of VEGF and also to
Placental Growth Factor resulting in higher efficiency
[3, 4]. Based on these findings advantages of Aflibercept
over Ranibizumab in clinical efficacy have been pro-
posed [4, 9]. Our data, collected in the real-life clinical
setting, do not confirm these results. Why not, remains
incompletely understood and calls for further research.
It can be speculated that the research protocols for the
Ranibizumab treatment in the VIEW studies led to add-
itional injections that are considered unnecessary in
clinical practice. As Aflibercept poses the ‘newbie’ in
the group of anti-VEGF-substances, further real-life
data is yet to be collected. Further research should also
explore ophthalmologists’ attitudes towards anti-VEGF
treatments. In our study, the decision whether to start
with Aflibercept or Ranibizumab was fully at the discre-
tion of the treating physician and we expected that
equipoise was present. Nevertheless we observed con-
siderable differences of baseline BCVA and CFT be-
tween the two groups indicating that they applied some
sort of tacit algorithm. A better understanding of cri-
teria guiding ophthalmologists’ decisions could help
depicting accepted management principles.
Our findings in context of Literature
To our knowledge, this is the first study comparing
Ranibizmab’s and Aflibercept’s efficacy in a real-life
setting. We are aware of one recent study by Johnston
and colleagues who counted the injection frequency
and summarized the expenditures of Ranibizumab and
Aflibercept treatments using health insurance claims
data from the United States [13]. Concordant to our
results, they found no statistical differences between
the two drugs.
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Strengths and limitations
The strength of this study lies in the early evaluation of
this topic as Swiss authorities approved Eylea only in
November 2012. Therefore it will contribute to a better
understanding of Aflibercept’s role in a real-life clinical
setting. Studies like ours have the potential to quantify
effects of treatments as they occur in clinical practice.
This has many reasons. Among them, the selection of
patients receiving care is not as rigorous as it usually is
in controlled experiments. Moreover, even in a highly
standardized clinical environment, the way of patient
work-up and follow-up is less intensive as in many stud-
ies but follows the laws of standard care. Both aspects
bear the potential of larger effects in clinical trials as
possibly observed in daily clinical routine. As a limita-
tion one must consider the non-randomised nature of
the study, where selection bias cannot unerringly be ex-
cluded. Actually, we found differences in the baseline
characteristics between the two groups in terms of visual
acuity and central foveal thickness indicating that the ex-
perienced ophthalmologists enrolled in this study ap-
plied some tacit selection mechanism. However, even
though a clinical protocol can never be replaced, the
study was conducted with a rigorous work-up protocol.
Moreover, the analysis corrected for different baseline
values and also excluded the measurements of the load-
ing phase to make groups more comparable. Finally, the
study was of limited size and thus, estimates were im-
precise warranting further confirmation in new studies.
Implications for practice
This study provided anti-VEGF drugs according to the
popular PRN approach. Our results, thus, are particu-
larly useful for all those retinologists using this regimen.
The retrospective analysis made in this cohort of pa-
tients did not detect significant differences between rani-
bizumab and aflibercept suggesting that both drugs
could be used as first line therapies. Given that the price for
both substances is identical (CHF 1067.-/dose) [15], prefer-
ential use of one substance for economic reasons - as could
be the case with Bevacizumab and Ranibizumab - might
play no role in the competition between Ranibizumab and
Aflibercept. We presume that further practical experi-
ence and research will allow defining the clinical niches
where the two drugs show their optimal efficacy profile.
Latest evidence [16–23] was able to prove Aflibercept’s
utility as a ‘salvage therapy’ in cases of suspected tachy-
phylaxis [24–26] to Ranibizumab, with gain in visual
acuity and/or reduction of CFT after conversion. Fur-
thermore, clinical observation and results from case re-
ports suggest that patients with serous PED might
benefit from treatment with Aflibercept [27, 28]. But
this observation yet needs to be backed up with experi-
mental clinical data.
Conclusion
The claimed advantages of Aflibercept, the new concur-
rent to Ranibizumab in nvAMD management, did not
materialize in this one-year clinical analysis under real-
life circumstances. The present study suggests that both
drugs are equivalent in terms of visual and anatomical
outcomes. However, further well designed comparative
studies investigating the two drugs in a PRN treatment
regimen evaluating the potential clinical advantages of
Aflibercept over Ranibizumab as first-line therapy in pa-
tients with nvAMD should be conducted.
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